During President Ali’s first term, Guyana’s healthcare system saw tremendous transformation. Among the most visible are six (6) new regional hospitals; expansion in telemedicine that saw many telemedicine sites set up, especially targeting remote/hinterland communities; a specialised maternal and pediatric health facility under construction; introduction and planning of digital health systems; and increases in trained healthcare workers.
There has been notable advancement in our biomedical capabilities as well. Dr. Frank Anthony, the returning Health Minister in President Ali’s second term, speaking at a health conference last October, highlighted that Guyana can now sequence viruses and track variants, underscoring a major leap in genomic laboratory capability. Guyana has been steadily growing its capability in healthcare and now stands at a turning point where health, technology, and national development intersect. The government’s vision for the next five years is not just about improving hospitals or producing more doctors. It is about reshaping the country into a recognised centre for life sciences and biotechnology.
This ambition builds on real progress achieved to date, as well as the critical partnerships with world-class institutions such as Mount Sinai and Johns Hopkins, which show that Guyana is already attracting attention as a serious player. These are not isolated gestures but part of a deliberate effort to raise standards in healthcare. More recently, the President challenged the University of Guyana to expand its medical program to increase access and equity by ensuring that qualified students, especially from outlying regions, can pursue their passion for becoming doctors and help to meet the increasing human resource demand in healthcare.
With these foundations in place, the 2025-2030 People’s Progressive Party / Civic’s Manifesto proposed a life sciences biopark as the natural next step in the evolution of the healthcare ecosystem. The park would include a biobank, facilities for diagnostics and vaccine manufacturing, and a new institute for tropical medicine. It is also envisioned to provide clinical trial capacity, foster collaboration between academic researchers and biomedical innovators, and serve as a data hub powered by advanced analytics and artificial intelligence.
To achieve this ambitious goal, Guyana is partnering with the European Union to establish the biopark under the Global Gateway initiative. This project, developed in partnership with the award-winning Charleroi Biopark in Belgium, aims to build a sustainable ecosystem for the local health and pharmaceutical sectors.
The urgency of this vision becomes even clearer when viewed through the lens of recent global challenges. The COVID-19 pandemic reminded the world how vulnerable countries can be when they lack the ability to test, manufacture, or innovate quickly. Building this park would give Guyana more control over its own health security while contributing to regional resilience. For ordinary citizens, this means better access to modern treatments, reduced dependence on overseas referrals, and more opportunities to benefit directly from innovations developed at home. It would also create jobs, draw investment, and inspire the next generation of Guyanese scientists and entrepreneurs.
Most of all, the park shows continuity. Upgraded hospitals, increased laboratory capabilities, expanded medical education, and international collaborations have already laid the groundwork. The life sciences initiative builds on that momentum and extends it, weaving health into the broader fabric of national transformation.
Finally, Guyana is also expanding its legislative and regulatory framework for pharmaceuticals and biologics. With support from PAHO and WHO, the country has begun reviewing and redrafting outdated drug laws dating back to the 1970s, preparing modern legislation to be tabled in Parliament. Work is underway to benchmark Guyana’s regulatory authority against global standards using the WHO Global Benchmarking Tool, and an institutional development plan is being developed to strengthen oversight. These reforms, combined with existing food and drug regulations on licensing and labelling, will ensure that new vaccine and pharmaceutical manufacturing meets the highest international standards.
This is a bold vision, but Guyana isn’t shying away from boldness when the well-being of its people is on the line. With clear political will, growing professional expertise, and strong global partnerships, the next five years could see Guyana emerge not only as a provider of world-class healthcare but also as a recognised leader in research and innovation.
ABOUT DR. KOFI DALRYMPLE
Dr. Kofi Dalrymple is the Presidential Adviser on Tertiary Education Reform. An academic, engineer, scientist, and entrepreneur, Dr. Dalrymple is the Dean of the Faculty of Engineering and Technology at the University of Guyana. He is a graduate of the University of Guyana, the University of the West Indies, and the University of South Florida.